Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI

作者：Ming-Ran Xu, Rong-Fang Dai, Qing-Qi Wei, Jun Wang, Yue-Ying Feng, Ying Hu · 发表于：American Journal of Alzheimer s Disease & Other Dementias® · 年份：2022 · DOI：10.1177/15333175221115247 · 被引用次数：10 · 研究领域：Dementia and Cognitive Impairment Research、Advanced Glycation End Products research、Intensive Care Unit Cognitive Disorders

The AD7c-NTP is a promising biomarker for AD diagnosis. However, the exact urinary AD7c-NTP concentration to differentiate AD from the mild cognitive impairment (MCI) remains inconclusive. We enrolled 98 and 90 clinical defined AD and MCI patients, respectively, and access their cognition impairment with Neuropsychiatric Inventory (NPI) and Mental State Examination (MMSE) along with their urinary AD7c-NTP. We demonstrated that urinary AD7c-NTP level in sequence from high to low was AD, MCI, and healthy groups ( P < .01), and the AD7c-NTP was positively and negatively correlated with the NPI and MMSE scores, respectively. Additionally, AD7c-NTP well-matched NPI subscale scores, including agitation, depression, and apathy ( P < .05). Importantly, the optimal cut-off AD7c-NTP level to distinguish the AD and MCI was .94 ng/mL (sensitivity 85.71% & specificity 73.91%). Conclusively, urinary AD7c-NTP could be used for cognition impairment evaluation and differentiated diagnosis of AD and MCI.